Skip to main content

Table 2 Baseline characteristics divided by LGE status

From: T1 and T2 mapping for evaluation of myocardial involvement in patients with ANCA-associated vasculitides

  LGE negative n = 21 LGE positive n = 16 p
Cardiovascular risk factors
 Diabetes 3 (14%) 4 (25%) 0.41
 Hypertension 8 (38%) 5 (31%) 0.67
 Smokinga 8 (38%) 5 (31%) 0.98
 Hyperlipidemia 2 (10%) 4 (25%) 0.21
 Family history of CVD 6 (29%) 5 (31%) 0.86
 Obesity (BMI ≥ 30 kg/m2) 6 (29%) 3 (19%) 0.49
Symptoms (multiple possible)
 Angina 2 (10%) 4 (25%) 0.21
 Dyspnea 8 (38%) 8 (50%) 0.55
 Palpitations 2 (10%) 2 (13%) 0.72
 Syncope - 1 (6%) 0.25
 ECG abnormality 5 (24%) 6 (38%) 0.37
Years since diagnosis
  < 1 8 (38%) 4 (25%) 0.57
 1–4 5 (24%) 6 (38%) 0.63
 5–9 7 (33%) 4 (25%) 0.67
  ≥ 10 1 (5%) 2 (13%) 0.39
Disease Activity
 BVAS 4 (1–19) 6 (2.5–12.5) 0.91
Hematocrit 0.39 (0.32–0.41) 0.41 (0.38–0.44) 0.10
Medication
 Beta-blockers 5 (24%) 4 (25%) 0.93
 ARB 10 (48%) 4 (25%) 0.16
 ASA - 5 (31%)  
 CCB 6 (29%) 2 (13%) 0.24
 Statins 1 (5%) 2 (13%) 0.37
 Diuretics 4 (19%) 4 (25%) 0.66
 Steroids 21 (100%) 16 (100%) 0.16
 NSAID 1 (5%) -  
 Antibodies 2 (10%) -  
 Cyclophosphamide 11 (52%) 6 (38%) 0.67
 Azathioprine 1 (5%) 3 (19%) 0.18
 Methotrexate 2 (10%) 3 (19%) 0.42
  1. All values are n (%) or interquartile ranges. CVD cardiovascular disease, BMI body mass index, ECG electrocardiogram, BVAS Birmingham vasculitis activity score, ARB angiotensin receptor blockers, ASA acetylsalicylic acid, CCB calcium channel blockers, NSAID nonsteroidal anti-inflammatory drug
  2. aCurrent or ever-smokers